|Mr. Chen Schor||Co-Founder, Pres, CEO & Director||676.45k||N/A||1972|
|Dr. Joan Mannick M.D.||Co-Founder & Chief Medical Officer||509.06k||N/A||1959|
|Ms. Meredith Manning||Chief Commercial Officer||393.08k||N/A||1972|
|Mr. John J. McCabe CPA, CPA||VP of Fin.||N/A||N/A||1968|
|Dr. Lloyd Klickstein||Chief Scientific Officer||N/A||N/A||N/A|
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases primarily in the United States. Its lead program is targeting the selective inhibitor of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is an orally administered, TORC1 inhibitor, which completed Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as urinary tract infections, neurodegenerative diseases, and heart failure. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
resTORbio, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.